文献速递妇科产科

非裔美国女性心血管代谢合并症与上皮性卵巢癌风险

Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
PubMed 文献 · Gynecol Oncol · 2020-04-30

基于AACES研究593例卵巢癌患者和752例对照,分析高血压、高脂血症、糖尿病与上皮性卵巢癌风险的关系。高血压与风险升高相关(aOR=1.32),糖尿病和高脂血症与风险降低相关(aOR分别为0.67和0.61)。使用降压、降糖或降脂药物与风险降低相关。

要点

  • 高血压与非裔美国女性上皮性卵巢癌风险升高相关(aOR=1.32)。
  • 糖尿病和高脂血症与该人群上皮性卵巢癌风险降低相关。
  • 使用降压、降糖或降脂药物与上皮性卵巢癌风险降低相关。

核心结论

  • 在该非裔美国女性人群中,高血压与上皮性卵巢癌风险升高相关,而糖尿病和高脂血症与风险降低相关。
  • 使用降压药、降糖药或降脂药与上皮性卵巢癌风险降低相关,可能对风险降低策略有启示。

研究设计与样本

  • 数据来自非裔美国癌症流行病学研究(AACES),纳入593例卵巢癌患者和752例对照。
  • 参与者自报高血压、高脂血症、糖尿病病史及当前用药情况,采用多因素逻辑回归分析关联。

主要发现

  • 高血压与上皮性卵巢癌风险升高相关(aOR=1.32,95%CI=1.01-1.73)。
  • 糖尿病与上皮性卵巢癌风险降低相关(aOR=0.67,95%CI=0.49-0.91)。
  • 高脂血症与上皮性卵巢癌风险降低相关(aOR=0.61,95%CI=0.47-0.80)。
  • 使用降糖药与上皮性卵巢癌风险呈负相关。
  • 在整体研究人群中,使用降脂药(主要为他汀类)与上皮性卵巢癌风险呈负相关。

临床怎么用

  • 在评估非裔美国女性上皮性卵巢癌风险时,可关注高血压、糖尿病和高脂血症等心血管代谢合并症及用药史。
  • 降压、降糖或降脂药物的使用可能与上皮性卵巢癌风险降低相关,但需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies that have examined the association between cardiovascular comorbidities and epithelial ovarian cancer (EOC) have yielded inconsistent results. It remains unknown whether cardiometabolic disease is associated with EOC in African American (AA) women, who have a higher prevalence of cardiovascular disease and lower risk of EOC than White women. Here, we estimate the effect of cardiovascular comorbid conditions and EOC risk among AA women. METHODS: Data were available from 593 ovarian carcinoma patients and 752 controls enrolled in the African American Cancer Epidemiology Study (AACES). Participants were asked to self-report a history of hypertension, hyperlipidemia, and diabetes and any current medication use. The relationship between hypertension, hyperlipidemia, diabetes, and medications taken for these conditions was determined using multivariate logistic regression. RESULTS: Hypertension was associated with an increased risk (adjusted odds ratio (aOR) = 1.32, 95% confidence interval (CI) = 1.01, 1.73), whereas diabetes and hyperlipidemia were associated with a decreased risk (aOR = 0.67, 95% CI = 0.49, 0.91 and aOR = 0.61, 95% CI = 0.47, 0.80, respectively) of EOC. Use of anti-diabetic medication was inversely associated with EOC risk, as was use of lipid lowering medications (in the overall study population), which were predominantly statins. Among women with hypertension, use of anti-hypertensive medications was inversely associated with EOC risk, with associations that were most pronounced for diuretics, ARBs and ACE inhibitors. CONCLUSION: Hypertension was associated with an increased EOC risk in this patient population, whereas an inverse association was observed for diabetes and hyperlipidemia. The decreased risk of EOC identified with use of anti-hypertensive, anti-diabetes or lipid-lowering medications could have implications for risk reduction strategies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Staples JN, Peres LC, Camacho F, et al. Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES). Gynecol Oncol. 2020. PMID: 32362566. doi:10.1016/j.ygyno.2020.04.700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。